Roberto Hegg

Researcher Next ID · RN-006234

Researcher · Medicine

São Paulo, Brazil

Not currently recruitingFunding unknown

Research interests

Medicine

Biochemistry, Genetics and Molecular Biology

Advanced Breast Cancer Therapies

Breast Cancer Treatment Studies

HER2/EGFR in Cancer Research

Cancer Treatment and Pharmacology

Women's cancer prevention and management

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)32531-9
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)31953-x
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1809615
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt182
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1113216

No projects listed.